Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly

Context: First-generation somatostatin receptor ligands (fg-SRLs) represent the mainstay of medical therapy for acromegaly, but they provide biochemical control of disease in only a subset of patients. Various pretreatment biomarkers might affect biochemical response to fg-SRLs. Objective: To identi...

Descripción completa

Detalles Bibliográficos
Autores: Coopmans, EC, Korevaar, TIM, van Meyel, SWF, Daly, AF, Chanson, P, Brue, T, Delemer, B, Hana, V, Colao, A, Carvalho, D, Jaffrain-Rea, ML, Stalla, GK, Fajardo-Montanana, C, Beckers, A, van der Lely, AJ, Petrossians, P, Neggers, SJCMM
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p9236
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/9236
Access Level:acceso abierto
Palabra clave:acromegaly
first-generation somatostatin receptor ligands
biochemical response
id ES_32a35cc7e7e03423a2d8d70c7d41e5c4
oai_identifier_str oai:fisabio.fundanetsuite.com:p9236
network_acronym_str ES
network_name_str España
repository_id_str
spelling Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in AcromegalyCoopmans, ECKorevaar, TIMvan Meyel, SWFDaly, AFChanson, PBrue, TDelemer, BHana, VColao, ACarvalho, DJaffrain-Rea, MLStalla, GKFajardo-Montanana, CBeckers, Avan der Lely, AJPetrossians, PNeggers, SJCMMacromegalyfirst-generation somatostatin receptor ligandsbiochemical responseContext: First-generation somatostatin receptor ligands (fg-SRLs) represent the mainstay of medical therapy for acromegaly, but they provide biochemical control of disease in only a subset of patients. Various pretreatment biomarkers might affect biochemical response to fg-SRLs. Objective: To identify clinical predictors of the biochemical response to fg-SRLs monotherapy defined as biochemical response (insulin-like growth factor (IGF)-1 <= 1.3 x ULN (upper limit of normal)), partial response (>20% relative IGF-1 reduction without normalization), and nonresponse (<= 20% relative IGF-1 reduction), and IGF-1 reduction. Design: Retrospective multicenter study. Setting: Eight participating European centers. Methods: We performed a meta-analysis of participant data from 2 cohorts (Rotterdam and Liege acromegaly survey, 622 out of 3520 patients). Multivariable regression models were used to identify predictors of biochemical response to fg-SRL monotherapy. Results: Lower IGF-1 concentration at baseline (odds ratio (OR) = 0.82, 95% confidence interval (CI) 0.72-0.95 IGF-1 ULN, P = .0073) and lower bodyweight (OR = 0.99, 95% CI 0.98-0.99 kg, P = .038) were associated with biochemical response. Higher IGF-1 concentration at baseline (OR = 1.40, (1.19-1.65) IGF-1 ULN, P <= .0001), the presence of type 2 diabetes (oral medication OR = 2.48, (1.43-4.29), P = .0013; insulin therapy OR = 2.65, (1.02-6.70), P = .045), and higher bodyweight (OR = 1.02, (1.01-1.04) kg, P = .0023) were associated with achieving partial response. Younger patients at diagnosis are more likely to achieve nonresponse (OR = 0.96, (0.94-0.99) year, P = .0070). Baseline IGF-1 and growth hormone concentration at diagnosis were associated with absolute IGF-1 reduction (beta = 0.90, standard error (SE) = 0.02, P <= .0001 and beta = 0.002, SE = 0.001, P = .014, respectively). Conclusion: Baseline IGF-1 concentration was the best predictor of biochemical response to fg-SRL, followed by bodyweight, while younger patients were more likely to achieve nonresponse.ENDOCRINE SOC2020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/9236JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISMISSN: 0021972XISSNe: 19457197reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p92362026-06-11T12:45:17Z
dc.title.none.fl_str_mv Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
title Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
spellingShingle Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
Coopmans, EC
acromegaly
first-generation somatostatin receptor ligands
biochemical response
title_short Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
title_full Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
title_fullStr Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
title_full_unstemmed Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
title_sort Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
dc.creator.none.fl_str_mv Coopmans, EC
Korevaar, TIM
van Meyel, SWF
Daly, AF
Chanson, P
Brue, T
Delemer, B
Hana, V
Colao, A
Carvalho, D
Jaffrain-Rea, ML
Stalla, GK
Fajardo-Montanana, C
Beckers, A
van der Lely, AJ
Petrossians, P
Neggers, SJCMM
author Coopmans, EC
author_facet Coopmans, EC
Korevaar, TIM
van Meyel, SWF
Daly, AF
Chanson, P
Brue, T
Delemer, B
Hana, V
Colao, A
Carvalho, D
Jaffrain-Rea, ML
Stalla, GK
Fajardo-Montanana, C
Beckers, A
van der Lely, AJ
Petrossians, P
Neggers, SJCMM
author_role author
author2 Korevaar, TIM
van Meyel, SWF
Daly, AF
Chanson, P
Brue, T
Delemer, B
Hana, V
Colao, A
Carvalho, D
Jaffrain-Rea, ML
Stalla, GK
Fajardo-Montanana, C
Beckers, A
van der Lely, AJ
Petrossians, P
Neggers, SJCMM
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv acromegaly
first-generation somatostatin receptor ligands
biochemical response
topic acromegaly
first-generation somatostatin receptor ligands
biochemical response
description Context: First-generation somatostatin receptor ligands (fg-SRLs) represent the mainstay of medical therapy for acromegaly, but they provide biochemical control of disease in only a subset of patients. Various pretreatment biomarkers might affect biochemical response to fg-SRLs. Objective: To identify clinical predictors of the biochemical response to fg-SRLs monotherapy defined as biochemical response (insulin-like growth factor (IGF)-1 <= 1.3 x ULN (upper limit of normal)), partial response (>20% relative IGF-1 reduction without normalization), and nonresponse (<= 20% relative IGF-1 reduction), and IGF-1 reduction. Design: Retrospective multicenter study. Setting: Eight participating European centers. Methods: We performed a meta-analysis of participant data from 2 cohorts (Rotterdam and Liege acromegaly survey, 622 out of 3520 patients). Multivariable regression models were used to identify predictors of biochemical response to fg-SRL monotherapy. Results: Lower IGF-1 concentration at baseline (odds ratio (OR) = 0.82, 95% confidence interval (CI) 0.72-0.95 IGF-1 ULN, P = .0073) and lower bodyweight (OR = 0.99, 95% CI 0.98-0.99 kg, P = .038) were associated with biochemical response. Higher IGF-1 concentration at baseline (OR = 1.40, (1.19-1.65) IGF-1 ULN, P <= .0001), the presence of type 2 diabetes (oral medication OR = 2.48, (1.43-4.29), P = .0013; insulin therapy OR = 2.65, (1.02-6.70), P = .045), and higher bodyweight (OR = 1.02, (1.01-1.04) kg, P = .0023) were associated with achieving partial response. Younger patients at diagnosis are more likely to achieve nonresponse (OR = 0.96, (0.94-0.99) year, P = .0070). Baseline IGF-1 and growth hormone concentration at diagnosis were associated with absolute IGF-1 reduction (beta = 0.90, standard error (SE) = 0.02, P <= .0001 and beta = 0.002, SE = 0.001, P = .014, respectively). Conclusion: Baseline IGF-1 concentration was the best predictor of biochemical response to fg-SRL, followed by bodyweight, while younger patients were more likely to achieve nonresponse.
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/9236
url https://fisabio.portalinvestigacion.com/publicaciones/9236
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ENDOCRINE SOC
publisher.none.fl_str_mv ENDOCRINE SOC
dc.source.none.fl_str_mv JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
ISSN: 0021972X
ISSNe: 19457197
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869405688253382656
score 15.812429

Similares en LA Referencia